Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Blinatumomab
Related studies linked through entity extraction aliases.
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Status
- RECRUITING
- Phase
- PHASE2
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
- Status
- RECRUITING
- Phase
- PHASE2
Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Immune Reconstitution After Allo-HSCT and Blinatumomab
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
- Status
- TERMINATED
- Phase
- PHASE1
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
- Status
- RECRUITING
- Phase
- PHASE2
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation
- Status
- UNKNOWN
- Phase
- N/A
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL
- Status
- RECRUITING
- Phase
- PHASE2
Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL
- Status
- COMPLETED
- Phase
- PHASE2
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
- Status
- RECRUITING
- Phase
- PHASE3
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT
- Status
- TERMINATED
- Phase
- PHASE2